A preclinical pharmacokinetics, pharmacodynamics and survival analysis of Seclidemstat in glioblastoma PDX models. This study will evaluate the effect of targeting LSD1 (lysine-specific histone demethylase 1A), a key enzyme that has increased expression in tumors of brain cancer patients.
We are testing Karyopharm’s first-in-class oral Selective Inhibitor of Nuclear Export (SINE) compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma.
A pharmacokinetic and pharmacodynamic assessment of FGFR inhibitor, infigratinib, for the treatment of glioblastoma. This collaboration focuses on targeting FGFR (fibroblast growth factor receptor) genetic alterations that have been shown to spur growth in malignant tumors.
Preclinical study in progress
Testing investigational agent infigratinib in glioblastoma